Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.41 |
| ▸ | ACE | P12821 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22772401 | 1.00 | MME (0.41) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22800060 | 1.00 | MME (0.41) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22772409 | 0.87 | F11 (0.39) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22772398 | 0.87 | F11 (0.39) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22772408 | 0.87 | F11 (0.39) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22772406 | 0.87 | F11 (0.39) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22800248 | 0.80 | ALDH1A1 (0.39) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22800234 | 0.80 | ALDH1A1 (0.39) | MMEACEALDH1A1MTNR1ATSHR | |
| SCHEMBL22800174 | 0.79 | KDM4E (0.44) | MMEACEALDH1A1 | |
| SCHEMBL22800767 | 0.79 | KDM4E (0.44) | MMEACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292801-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | MME 1198/4885ACE 615/4885ALDH1A1 3918/4885 |
| US-11292801-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN2, CAPN1 | MME 1198/4885ACE 615/4885ALDH1A1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.